MLNT - Melinta Therapeutics, Inc.
Melinta Therapeutics, Inc.
44 Whippany Road
http://www.melinta.com
Full Time Employees: 290
Ms. Jennifer A. Sanfilippo Interim CEO & Director N/A N/A 1979
Dr. Thomas A. Steitz Co-Founder N/A N/A N/A
Dr. Peter B. Moore Ph.D. Co-Founder N/A N/A N/A
Dr. William L. Jorgensen Co-Founder N/A N/A N/A
Mr. Peter J. Milligan CFO & Sec. N/A N/A 1968
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
Melinta Therapeutics, Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes various anti-infectives for the treatment of bacterial infectious diseases in North America. It offers Baxdela, a monotherapy treatment of adult patients with acute bacterial skin or skin structure infections (ABSSSIs); Vabomere, an IV antibiotic used in treatment of gram-negative infections; Orbactiv, an IV antibiotic of the lipoglycopeptide class for the treatment of adult patients with ABSSSIs; and Minocin, a IV antibiotic of the tetracycline class with activity against gram-positive and gram-negative pathogens. The company has license agreements with Yale University, Medical Research Council, Wakunaga Pharmaceutical Co., Ltd., and CyDex Pharmaceuticals, Inc. Melinta Therapeutics, Inc. was founded in 2000 and is based in Morristown, New Jersey. On December 27, 2019, Melinta Therapeutics, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Melinta Therapeutics, Inc.'s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.